ArticleFrontiers in immunology2026
The ALP score: a novel composite index for prognostic risk stratification to chemo-immunotherapy in advanced non-small cell lung cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the value of a novel composite index, the ALP score (calculated as the product of lymphocyte count and serum albumin), in predicting the risk of early progression to chemotherapy combined with immune checkpoint inhibitors (ICIs) in patients with driver mutation-negative advanced non-small cell lung cancer (NSCLC). Methods: Clinical data from 433 patients with advanced NSCLC who received first-line chemoimmunotherapy were retrospectively collected. Independent risk factors for early progression (defined as progressive disease, PD) were identified using univariate and multivariate logistic regression analyses. The predictive power of the ALP score for PD was evaluated, and its nonlinear relationship with risk was explored using restricted cubic splines (RCS). Ten machine learning models and the SHAP interpretability technique were further employed to validate the importance of the ALP score. Results: Multivariate analysis identified the absence of liver metastasis and the absence of bone metastasis as independent protective factors against early progression, whereas lower lymphocyte count, lower albumin level, and lower Body Mass Index were identified as independent risk factors. The ALP score predicted PD with an AUC of 0.643, outperforming its individual components. Critically, multivariable analyses confirmed the ALP score as an independent predictor for both endpoints: patients in the highest score tertile had significantly lower risks of early progression (OR = 0.33, P = 0.001) and disease progression or death (HR = 0.65, P = 0.002) compared to the lowest tertile. RCS analysis revealed a significant nonlinear inverse relationship between the ALP score and PD risk (P<0.05). Machine learning models (best model AUC = 0.655) and SHAP analysis consistently confirmed the ALP score as a key predictive feature for disease progression. Conclusion: The ALP score, a composite index derived from routine laboratory parameters, serves as an accessible and practical prognostic marker associated with early progression risk and progression-free survival in patients with advanced NSCLC. Reflecting baseline systemic immune and nutritional readiness, it offers a practical and low-cost tool for clinical risk stratification in patients receiving chemo-immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.